Singlera Genomics Inks EU Distribution Deal With Pure Medical for cfDNA Assays

Original from: genomeweb

Singlera Genomics said on Tuesday that it has entered into a research and distribution agreement with EU-based international medical company Pure Medical for its cell-free DNA detection products.

Under the terms of the agreement, Singlera and Pure Medical will collaborate on the commercial distribution of Singlera's mTitan- and mGuard-based assays in several European countries. They will also work with local universities, hospital networks, and national healthcare systems on related research studies in western Europe.

Financial terms of the agreement were not disclosed.

Singlera's mTitan and mGuard platforms screen circulating cell-free DNA for signals associated with cancer. The patented methylation sequencing technology behind these platforms has been used to non-invasively detect methylation haplotypes from esophageal, colorectal, gastric, lung, liver, and pancreatic cancer, the company said.

"This distribution agreement represents an important step in our European business strategy to bring inexpensive early cancer detection and monitoring to the global patient population," Qiang Liu, chief operating officer of Singlera Genomics, said in a statement. "We hope that Singlera's methylation products can give clinicians an important tool for faster detection, diagnosis, and treatment of cancer."

Last week Singlera announced a research collaboration with the University of Pittsburgh to explore Singlera's BT-Reveal test for the early detection of pancreatic cancer.

Source: Singlera Genomics Inks EU Distribution Deal With Pure Medical for cfDNA Assays